Cannformatics, an early-stage biotechnology company, has unveiled a groundbreaking advancement in the field of medical cannabis treatment for Autism Spectrum Disorder (ASD).

Their recent publication in Nature's Scientific Reports highlights the use of Cannabis-Responsive (C-Res) biomarkers and machine learning to pioneer personalized therapies for ASD and various neurological conditions such as Alzheimer's Disease, Multiple Sclerosis and PTSD.

Advancing Autism Spectrum Disorder Therapy With Machine Learning

Cannformatics reported that the research introduces an innovative approach using C-Res biomarkers to differentiate ASD patient cohorts based on metabolic imbalances, paving the way for tailored therapies that extend beyond medical cannabis.

Dr. Itzhak Kurek, CEO and co-founder of Cannformatics, emphasizes the potential impact of C-Res biomarkers in identifying metabolic imbalances in children with autism.

“Our focus is on introducing a saliva-based lab testing service that empowers healthcare providers and patients to tailor and evaluate cannabis-based treatments with precision,” explained Dr. Kurek in a press release procured by Benzinga.

“The most important discovery to come out of the machine learning research was the ability of C-Res biomarkers to serve as a probe to identify metabolic imbalances in children with ASD. Ultimately, we want to positively impact all patients struggling with neurological and neuropsychiatric conditions by identifying the MOA and metabolic pathways underlying THC, CBD, CBG, and phytochemicals,” Dr. Kurek added.

The company reported preliminary results indicating the ability of machine learning to identify cannabinoid mechanisms and phytochemical entourage effects, streamlining the development of effective therapies.

Cannformatics also reported that its research sheds light on the therapeutic role of non-cannabinoid phytochemicals like terpenes, flavonoids and phytosterols in ASD treatment, illustrating the entourage effect.

Precision Cannabis Solutions

Headquartered in San Francisco, Cannformatics specializes in Cannabis-Responsive biomarkers for personalized cannabis treatment and product development.

The first phase, focused on ASD, is anticipated to launch within six months following the completion of the company's Series-A fundraising round.

Kenneth Epstein, CCO, and co-founder, highlighted the significance of Cannformatics' rigorously peer-reviewed data in validating cannabis' medical benefits and safety. 

Stay on top of the latest developments and investment opportunities in the cannabis industry at the Benzinga Cannabis Capital Conference, which is returning to Chicago on September 27-28. Get your tickets today before prices go up and secure a spot at the epicenter of cannabis investment, culture, politics and branding.

Photo by: Gerd Altmann via Pixabay.